This site is intended for healthcare professionals

Phase III trial data for Riavax shows extended survival in pancreatic cancer.- Samsung Pharm Co

Read time: 1 mins
Last updated:8th Jun 2021
Published:6th Jun 2021
Samsung Pharm Co., Ltd. announced that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called 'Riavax or GV 1001. Riavax is a peptide drug derived from human telomerase consisting of 16 amino acids. It has been developed as an immunotherapeutic drug for pancreatic cancer which works to activate immune cells to attack the cancer cells.
Condition: Pancreatic Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest